Ultrastructural analysis of candida albicans when exposed to silver nanoparticles

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Vazquez Muñoz, Roberto ^a   Avalos Borja, Miguel ^b,c   Castro Longoria, Ernestina ^a  

^a CENTRO DE INVESTIGACIÓN CIENTÍFICA Y DE EDUCACIÓN SUPERIOR DE ENSENADA   (Mexico)

^b INSTITUTO POTOSINO DE INVESTIGACIÓN CIENTÍFICA Y TECNOLÓGICA   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; SILVER NANOPARTICLE; ANTIFUNGAL AGENT; METAL NANOPARTICLE; SILVER; SILVER DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANDIDA ALBICANS; CELL DEATH; CELL INFILTRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG MECHANISM; DRUG PENETRATION; DRUG RELEASE; FUNGAL CELL; FUNGICIDAL ACTIVITY; IC50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRUCTURE ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST;

CANDIDA ALBICANS;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; HUMANS; METAL NANOPARTICLES; MICROBIAL SENSITIVITY TESTS; SILVER; SILVER COMPOUNDS;

EID: 84907759025     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108876     Document Type: Article

References (51)

1. Pfaller M, Diekema D (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-63.
2. Espinel-Ingroff A, Canton E, Peman J, Rinaldi MG, Fothergill AW (2009) Comparison of 24-Hour and 48-Hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. and other yeasts. J Clin Microbiol 47: 2766-2771. DOI: 10.1128/JCM.00654-09.
3. Lionakis MS, Netea MG (2013) Candida and host determinants of susceptibility to invasive candidiasis. PLoS Pathog 9: e1003079. doi:10.1371/journal.-ppat.1003079.
4. Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJS (2013) Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 62: 10-24 DOI 10.1099/jmm.0.045054-0.
5. Moran G, Coleman D, Sullivan D (2012) An introduction to the medically important Candida species. In Candida and candidiasis, edn 2. Edited by Calderone RA, Clancy CJ. ASM Press (pp. 387-401).
6. Papon N, Courdavault V, Clastre M, Bennett RJ (2013) Emerging and emerged pathogenic Candida species: Beyond the Candida albicans paradigm. PLoS Pathog 9: e1003550. doi:10.1371/journal.ppat.1003550.
7. Cuéllar-Cruz M, Vega-González A, Mendoza-Novelo B, López-Romero E, Ruiz-Baca E, et al. (2012) The effect of biomaterials and antifungals on biofilm formation by Candida species: a review. Eur J Clin Microbiol Infect Dis 31: 2513-2527.
8. Stevens D, White T, Perlin D, Selitrennikoff C (2005) Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Micr Infec Dis 51: 173-178.
9. Fothergill AW, Rinaldi MG, Sutton DA (2006) Antifungal susceptibility testing. Infect Dis Clin N Am 20: 699-709.
10. Vandeputte P, Ferrari S, Coste AT (2012) Antifungal resistance and new strategies to control fungal infections. Int J Microbiol 2012: 713687.
11. Cassell G, Mekalanos J (2001) Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance. J Amer Med Assoc 285: 601-605.
12. Dastjerdi R, Montazer M (2010) A review on the application of inorganic nano-structured materials in the modification of textiles: focus on anti-microbial properties. Colloids Surf B Biointerfaces 79: 5-18.
13. Le AT, Le TT, Tran HH, Dang DA, Tran QH, et al. (2012) Powerful colloidal silver nanoparticles for the prevention of gastrointestinal bacterial infections. Adv Nat Sci Nanosci Nanotechnol 3: 045007.
14. Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Giannini MM (2013) Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 62: 10-24.
15. White RJ (2001) An historical overview of the use of silver in wound management. Br J Nurs 10 (15 Suppl. 2), S3-S8.
16. Hidalgo E, Dominguez C (1998) Study of cytotoxicity mechanisms of silver nitrate in human dermal fibroblasts. Toxicol Lett 98: 169-179.
17. White J, Powell A, Brady K, Russell-Jones R (2003) Severe generalized argyria secondary to ingestion of colloidal silver protein. Clin Exp Dermatol 28: 254-256.
18. Asharani PV, Mun GLK, Hande MP, Valiyaveettil S (2009) Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano 3: 279-290.
19. Kwon HB, Lee JH, Lee SH, Lee AY, Choi JS, et al. (2009) A case of argyria following colloidal silver ingestion. Ann Dermatol 21: 308-310.
20. Lansdown ABG (2006). Silver in health care: Antimicrobial effects and safety in use. Curr Probl Dermatol 33: 17-34.
21. Kim KJ, Sung WS, Suh BK, Moon SK, Choi JS, et al. (2009) Antifungal activity and mode of action of silver nano-particles on Candida albicans. Biometals 22: 235-242.
22. Rai M, Yadav A, Gade A (2009) Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 27: 76-83.
23. Huh AJ, Kwon YJ (2011) "Nanoantibiotics": A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J. Control Release 156: 128-145.
24. Kim KJ, Sung WS, Moon SK, Choi JS, Kim JG, et al. (2008) Antifungal effect of silver nanoparticles on dermatophytes. J Microbiol Biotechnol 18: 1482-1484.
25. Roe D, Karandikar B, Bonn-Savage N, Gibbins B, Roullet JB (2008) Antimicrobial surface functionalization of plastic catheters by silver nanoparticles. J Antimicrob Chemoth 61: 869-876.
26. Ghosh S, Kaushik R, Nagalakshmi K, Hoti SL, Menezes GA, et al. (2010) Antimicrobial activity of highly stable silver nanoparticles embedded in agaragar matrix as a thin film. Carbohyd Res 345: 2220-2227.
27. Prucek R, Tuček J, Kilianová M, Panáček A, Kvítek L, et al. (2011) The targeted antibacterial and antifungal properties of magnetic nanocomposite of iron oxide and silver nanoparticles. Biomaterials 32: 4704-4713.
28. Stevanović M, Škapin S, Braćko I, Milenković M, Petković J, et al. (2012) Poly(lactide-co-glycolide)/silver nanoparticles: Synthesis, characterization, antimicrobial activity, cytotoxicity assessment and ROS-inducing potential. Polymer 53: 2818-28.
29. Martinez-Gutierrez F, Boeglib L, Agostinho A, Morales E, Bach H, et al. (2013) Anti-biofilm activity of silver nanoparticles against different microorganisms. Biofouling 29: 651-660.
30. Nadworny P, Wang J, Tredget E, Burrell R (2008) Anti-inflammatory activity of nanocrystalline silver in a porcine contact dermatitis model. Nanomedicine 4: 241-251.
31. Jaya J, Sumit A, Jyutika R, Pratibha O, Sanjeev K, et al. (2009) Silver nanoparticles in therapeutics: Development of an antimicrobial gel formulation for topical use. Mol. Pharmaceutics 6: 1388-1401.
32. Rogers J, Parkinson C, Choi Y, Speshock J, Hussain S (2008) A preliminary assessment of silver nanoparticle inhibition of monkeypox virus plaque formation. Nanoscale Res Lett 3: 129-133.
33. Klasen HJ (2000) Historical review of the use of silver in the treatment of burns. I. Early uses. Burns 26: 117-138.
34. Li P, Li J, Wu C, Wu Q, Li J (2005) Synergistic antibacterial effects of b-lactam antibiotic combined with silver nanoparticles. Nanotechnology 16: 1912.
35. Shahverdi A, Fakhimi A, Shahverdi H, Minaian S (2007) Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli, Nanomedicine 3: 168-171.
36. Fayaz AM, Balaji K, Girilal M, Yadav R, Tech M, et al. (2010) Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: a study against gram-positive and gram-negative bacteria, Nanomedicine 6: 103-109.
37. Panáček A, Kolář M, Večeřová R, Prucek R, Soukupová J, et al. (2010) Antifungal activity of silver nanoparticles against Candida spp. Biomaterials 30: 6333-6340.
38. Hwang IS, Lee J, Hwang JH, Kim KJ, Lee DG (2012) Silver nanoparticles induce apoptotic cell death in Candida albicans through the increase of hydroxyl radicals. FEBS Journal, 279: 1327-1338.
39. Vector-Vita website. Available: http://vector-vita.narod.ru/Documents/papers/Antibacterial-medicines-eng.htm Accessed 2014 Sep 12.
40. Graybill JR, Burgess DS, Hardin TC (1997) Key issues concerning fungistatic versus fungicidal drugs. Eur J Clin Microbiol Infect Dis 16: 42-50.
41. Monteiro DR, Gorup LF, Silva S, Negri M, de Camargo ER, et al. (2011) Silver colloidal nanoparticles: antifungal effect against adhered cells and biofilms of Candida albicans and Candida glabrata. Biofouling, 27: 711-719.
42. Nasrollahi A, Pourshamsian KH, Mansourkiaee P (2011) Antifungal activity of silver nanoparticles on some of fungi. Int J Nano Dim 1: 233-239.
43. El-Sayed MA (2001) Some interesting properties of metals confined in time and nanometer space of different shapes. Accounts Chem Res 34: 257-264.
44. Pal S, Tak YK, Song JM (2007) Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gramnegative bacterium Escherichia coli. Am Soc Microbiol 73: 1712-1720.
45. Carlson C, Hussain SM, Schrand AM, Braydich-Stolle LK, Hess KL, et al. (2008) Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J Phys Chem: 112: 13608-13619.
46. Bühler V (2005) Excipients for pharmaceuticals - Povidone, crospovidone and copovidone. Berlin, Heidelberg, New York: Springer. 1-254.
47. Gajbhiye M, Kesharwani J, Ingle A, Gade A, Rai M (2009) Fungus-mediated synthesis of silver nanoparticles and their activity against pathogenic fungi in combination with fluconazole. Nanomedicine: Nanotech Bio and Med 5: 382-386.
48. Sousa A de, Mehta D, Leavitt RW (2006) Bactericidal activity of combinations of Silver-Water Dispersion™ with 19 antibiotics against seven microbial strains. Curr Sci 91: 926-9.
49. Sondi I, Salopek-Sondi B (2004) Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for gram-negative bacteria. J. Colloid Interface Sci 275: 177-182.
50. Ishida K, Ferreira Cipriano T, Miranda Rocha G, Weissmüller G, Gomes F, et al. (2013) Silver nanoparticle production by the fungus Fusarium oxysporum: nanoparticle characterization and analysis of antifungal activity against pathogenic yeasts. Mem Inst Oswaldo Cruz, Rio de Janeiro: 1-9.
51. Reidy B, Haase A, Luch A, Dawson KA, Lynch I (2013) Mechanisms of silver nanoparticle release, transformation and toxicity: A critical review of current knowledge and recommendations for future studies and applications. Materials 6: 2295-2350.